Suzhou Abogen Raises $300 Million to Support mRNA COVID Vaccine

Suzhou Abogen Biosciences, an mRNA company, raised $300 million to support development of its COVID-19 vaccine and other drug candidates. In August, Abogen completed a very large $720 million C funding. The company is focused on nucleic acid-based (RNA and DNA) therapeutics for cancer and infectious diseases. Its COVID mRNA vaccine was originally discovered by China 's Academy of Military Medical Sciences (AMMS) and partnered with Abogen. The new $300 million raise, considered a C+ round, was led by SoftBank Group Corp's Vision Fund and 5Y Capital. More details.... Share this with colleagues: // //